Relationships Among Pain, Depressed Mood, and Global Status in Fibromyalgia Patients: Post Hoc Analyses of a Randomized, Placebo-Controlled Trial of Milnacipran

Psychosomatics

Volumn 53, Issue 4, 2012, Pages 371-379

  Arnold, Lesley M ^a   Palmer, Robert H ^b   Gendreau, R Michael ^c   Chen, Wei ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Gendreau Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MILNACIPRAN; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DEPRESSION; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT GLOBAL IMPRESSION OF CHANGE; POST HOC ANALYSIS; PSYCHOLOGIC TEST; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; MIDDLE AGED; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICS;

ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CHRONIC PAIN; CYCLOPROPANES; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84868017655     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2012.02.005     Document Type: Article

References (38)

1. Wolfe F., Ross K., Anderson J., Russell I.J., Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38(1):19-28.
2. White K.P., Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001, 5(4):320-329.
3. Bennett R.M. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am 2009, 35(2):215-232.
4. Arnold L.M. Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry 2008, 69(Suppl 2):14-19.
5. Buskila D., Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain Headache Rep 2007, 11(5):333-338.
6. McCarberg BH: Clinical overview of fibromyalgia. Am J Ther, 11 Feb 15. [Epub ahead of print].
7. Bennett R.M., Jones J., Turk D.C., Russell I.J., Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007, 8:27.
8. Choy E., Perrot S., Leon T., Kaplan J., Petersel D., Ginovker A., et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res 2010, 10:102.
9. Arnold L.M., Leon T., Whalen E., Barrett J. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia. Psychosomatics 2010, 51(6):489-497.
10. Beck A.T., Steer R.A., Garbin M.G. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988, 8:77-100.
11. Aguglia A., Salvi V., Maina G., Rossetto I., Aguglia E. Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. J Affect Disord 2011, 128(3):262-266.
12. de Souza J.B., Potvin S., Goffaux P., Charest J., Marchand S. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin J Pain 2009, 25(2):123-127.
13. Bradley L.A. Pathophysiology of fibromyalgia. Am J Med 2009, 122:S22-S30.
14. Marks D.M., Shah M.J., Patkar A.A., Masand P.S., Park G.Y., Pae C.U. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009, 7:331-336.
15. Arnold L.M., Keck P.E., Welge J.A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000, 41(2):104-113.
16. O'Malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., Jackson J.L. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000, 15(9):659-666.
17. Krell H.V., Leuchter A.F., Cook I.A., Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005, 46(5):379-384.
18. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004, 19(Suppl 1):S15-S19.
19. Mease P.J. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med 2009, 122(12 Suppl):S44-S55.
20. Arnold L.M., Gendreau R.M., Palmer R.H., Gendreau J.F., Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62(9):2745-2756.
21. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33(2):160-172.
22. Burckhardt C.S., Clark S.R., Bennett R.M. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18(5):728-733.
23. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
24. Beck A.T., Steer R.A., Brown G.K. Manual for the Beck Depression Inventory-II 1996, Psychological Corporation, San Antonio, TX.
25. Retherford R.D., Choe M.K. Statistical models for causal analysis. New York: Wiley 1993.
26. Cohen J. Applied multiple regression/correlation analysis for the behavioral sciences 2003, L. Erlbaum Associates, Mahwah, NJ. 3rd ed.
27. Loehlin J.C. Latent variable models: an introduction to factor, path, and structural equation analysis 2004, L. Erlbaum Associates, Mahwah, NJ. 4rd ed.
28. Streiner D.L. Finding our way: an introduction to path analysis. Can J Psychiatry 2005, 50(2):115-122.
29. Bennett R.M., Kamin M., Karim R., Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003, 114(7):537-545.
30. Bennett R.M., Bushmakin A.G., Cappelleri J.C., Zlateva G., Sadosky A.B. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009, 36(6):1304-1311.
31. Marangell L.B., Clauw D.J., Choy E., Wang F., Shoemaker S., Bradley L., et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 2011, 152(1):31-37.
32. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50(9):2974-2984.
33. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136(3):432-444.
34. Geisser M.E., Clauw D.J., Strand V., Gendreau R.M., Palmer R., Williams D.A. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 2010, 149(2):373-378.
35. Hudson J.I., Arnold L.M., Bradley L.A., Choy E.H., Mease P.J., Wang F., et al. What makes patients with fibromyalgia feel better?. Correlations between Patient Global Impression of Improvement and changes in clinical symptoms and function: a pooled analysis of four randomized placebo-controlled trials of duloxetine. J Rheumatol 2009, 36(11):2517-2522.
36. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119(1-3):5-15.
37. Nakagawa A., Watanabe N., Omori I.M., Barbui C., Cipriani A., McGuire H., et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009, CD006529.
38. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373(9665):746-758.